Skip to main content
Sexual Health, HIV All East Research Group (SHARE)


Professor Chloe Orkin

  1. Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S, Bettacchi C, Brinson C, Philibert P, Lombaard J, St Clair M, Crauwels H, Ford SL, Patel P, Chounta V, D’Amico R, Vanveggel S, Dorey D, Cutrell A, Griffith S, Margolis DA, Williams PE, Parys W, Smith KY, Spreen WR. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. N Engl J Med. 2020 Mar 19;382(12):1124-1135. doi: 10.1056/NEJMoa1909512. Epub 2020 Mar 4. PMID: 32130806
  2. Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489; GS-US-380-1490 study investigators. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir- containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0. PMID: 32504574
  3. Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA; DRIVE-AHEAD Study Group. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis.2019 Feb 1;68(4):535-544. doi: 10.1093/cid/ciy540. PMID: 30184165; PMCID: PMC6355823
  4. Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M; EMERALD study group. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018 Jan;5(1):e23-e34. doi: 10.1016/S2352-3018(17)30179-0. Epub 2017 Oct 6. PMID: 28993180
  5. Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B, de Wet J, Rockstroh J, Lazzarin A, Rijnders B, Podzamczer D, Thalme A, Stoeckle M, Porter D, Liu HC, Cheng A, Quirk E, SenGupta D, Cao H. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017 May;4(5):e195-e204. doi: 10.1016/S2352-3018(17)30031-0. Epub 2017 Mar 2. PMID: 28259777
  6. Orkin C, Molina JM, Lombaard J, DeJesus E, Rodgers A, Kumar S, Martin E, Hanna G, Hwang C. Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis. Clin Infect Dis. 2020 Mar 17;70(7):1344-1352. doi: 10.1093/cid/ciz424. Erratum in: Clin Infect Dis. 2020 Jan 2;70(2):360. PMID: 31121015
  7. Orkin C, Eron JJ, Rockstroh J, Podzamczer D, Esser S, Vandekerckhove L, Van Landuyt E, Lathouwers E, Hufkens V, Jezorwski J, Opsomer M; AMBER study group. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. AIDS. 2020 Apr 1;34(5):707-718. doi: 10.1097/QAD.0000000000002463. PMID: 31833849
  8. Apea VJ, Wan YI, Dhairyawan R, Puthucheary ZA, Pearse RM, Orkin CM, Prowle JR. Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study. BMJ Open. 2021 Jan 17;11(1):e042140. doi: 10.1136/bmjopen-2020-042140. PMID: 33455936; PMCID: PMC7813387
  9. Cevik M, Haque SA, Manne-Goehler J, Kuppalli K, Sax PE, Majumder MS, Orkin C. Gender disparities in coronavirus disease 2019 clinical trial leadership. Clin Microbiol Infect. 2021 Jan 5:S1198-743X(20)30785-0. doi: 10.1016/j.cmi.2020.12.025. Epub ahead of print. PMID: 33418021; PMCID: PMC7785275
  10. Parry S, Bundle N, Ullah S, Foster GR, Ahmad K, Tong CYW, Balasegaram S, Orkin C. Implementing routine blood-borne virus testing for HCV, HBV and HIV at a London Emergency Department – uncovering the iceberg? Epidemiol Infect. 2018 Jun;146(8):1026-1035. doi: 10.1017/S0950268818000870. Epub 2018 Apr 17. PMID: 29661260

Professor Jane Anderson

  1. Pralat R, Burns F, Anderson J, Barber TJ. Can HIV-positive gay men become parents? How men living with HIV and HIV clinicians talk about the possibility of having children. Sociol Health Illn. 2021 Feb;43(2):281-298. doi:10.1111/1467-9566.13218. Epub 2020 Nov 22. PMID: 33222191
  2. Rosenfeld, D., & Anderson, J. (2020). ‘The own’ and ‘the wise’ as social support for older people living with HIV in the United Kingdom. Ageing and Society, 40(1), 188-204. doi:10.1017/S0144686X18000909
  3. Safreed-Harmon K, Anderson J, Azzopardi-Muscat N, Behrens GMN, d’Arminio Monforte A, Davidovich U, Del Amo J, Kall M, Noori T, Porter K, Lazarus JV. Reorienting health systems to care for people with HIV beyond viral suppression. Lancet HIV. 2019 Dec;6(12):e869-e877. doi: 10.1016/S2352-3018(19)30334-0. Epub 2019 Nov 24. PMID: 31776099
  4. Bristowe K, Clift P, James R, Josh J, Platt M, Whetham J, Nixon E, Post FA, McQuillan K, Ní Cheallaigh C, Murtagh F, Anderson J, Sullivan AK, Harding R. Towards person-centred care for people living with HIV: what core outcomes matter, and how might we assess them? A cross-national multi-centre qualitative study with key stakeholders. HIV Med. 2019 Sep;20(8):542-554. doi: 10.1111/hiv.12758. Epub 2019 Jun 4. PMID: 31162817
  5. Leber W, McMullen H, Anderson J, Marlin N, Santos AC, Bremner S, Boomla K, Kerry S, Millett D, Mguni S, Creighton S, Figueroa J, Ashcroft R, Hart G, Delpech V, Brown A, Rooney G, Sampson M, Martineau A, Terris-Prestholt F, Griffiths C. Promotion of rapid testing for HIV in primary care (RHIVA2): a cluster-randomised controlled trial. Lancet HIV. 2015 Jun;2(6):e229-35. doi: 10.1016/S2352-3018(15)00059-4. Epub 2015 Apr 28. PMID: 26423195
  6. Baggaley RF, Irvine MA, Leber W, Cambiano V, Figueroa J, McMullen H, Anderson J, Santos AC, Terris-Prestholt F, Miners A, Hollingsworth TD, Griffiths CJ. Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis. Lancet HIV. 2017 Oct;4(10):e465-e474. doi: 10.1016/S2352-3018(17)30123-6. Epub 2017 Jul 30. PMID: 28768604; PMCID: PMC5614770
  7. The future of HIV services in England:A Baylis, D Buck, J Anderson, J Jabbal, S Ross; London: King’s Fund 2017
  8. Glendinning E, Spiers J, Smith JA, Anderson J, Campbell LJ, Cooper V, Horne R; SUPA Group. A Qualitative Study to Identify Perceptual Barriers to Antiretroviral Therapy (ART) Uptake and Adherence in HIV Positive People from UK Black African and Caribbean Communities. AIDS Behav. 2019 Sep;23(9):2514-2521. doi: 10.1007/s10461-019-02670-x. PMID: 31520239; PMCID: PMC6766469
  9. Burch LS, Smith CJ, Anderson J, Sherr L, Rodger AJ, O’Connell R, Geretti AM, Gilson R, Fisher M, Elford J, Jones M, Collins S, Azad Y, Phillips AN, Speakman A, Johnson MA, Lampe FC. Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses. Lancet Public Health. 2016 Nov;1(1):e26-e36. doi: 10.1016/S2468-2667(16)30002-0. PMID: 28299369; PMCID: PMC5341147
  10. Spiers J, Smith JA, Poliquin E, Anderson J, Horne R. The Experience of Antiretroviral Treatment for Black West African Women who are HIV Positive and Living in London: An Interpretative Phenomenological Analysis. AIDS Behav. 2016 Sep;20(9):2151-63. doi: 10.1007/s10461-015-1274-9. PMID: 26767539

Dr Vanessa Apea

  1. Apea V. Closing the gap on health inequalities: learning from HIV care. British Journal of Healthcare Management. 2020 Oct 2;26(10):1-4.
  2. Apea VJ, Wan YI, Dhairyawan R, Puthucheary ZA, Pearse RM, Orkin CM, Prowle JR. Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study. BMJ Open. 2021 Jan 17;11(1):e042140. doi: 10.1136/bmjopen-2020-042140. PMID: 33455936; PMCID: PMC7813387

Dr Rageshri Dhairyawan

  1. Dhairyawan R, Okhai H, Hill T, Sabin C. Antiretroviral treatment uptake and outcomes in heterosexual people living with HIV in the United Kingdom according to ethnic group. BHIVA conference abstract published in HIV MEDICINE, Nov 2020. Accepted for full publication in AIDS, 2021.
  2. Solomon D, Tariq S, Alldis J, Burns F, Gilson R, Sabin C, Sherr L, Pettit F, Dhairyawan R. Ethnic inequalities in mental health and socioeconomic status among older women living with HIV: results from the PRIME Study. Sex Transm Infect. 2021 Mar 29:sextrans-2020-054788. doi: 10.1136/sextrans-2020-054788. Epub ahead of print. PMID: 33782143.
  3. Orkin C, Flanagan S, Wallis E, Ireland G, Dhairyawan R, Fox J, Nandwani R, O'Connell R, Lascar M, Bulman J, Reeves I, Palfreeman A, Foster GR, Ahmad K, Anderson J, Tong CY, Lattimore S. Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the "Going Viral" campaign. HIV Med. 2016 Mar;17(3):222-30. doi: 10.1111/hiv.12364. PMID: 26919291.

Dr John Thornhill

  1. Martin GE, Sen DR, Pace M, Robinson N, Meyerowitz J, Adland E, Thornhill JP, Jones M, Ogbe AT, Parolini L, Olejniczak N, Zacharopoulou P, Brown H, Willberg C, Nwokolo N, Fox J, Fidler S, Haining WN, Frater J. Epigenetic features of HIV-induced T-cell exhaustion persist despite early antiretroviral therapy. Front Immunol. 2021 (in press)
  2. Thornhill J, Orkin C. Long-acting injectable HIV therapies: the next frontier. Curr Opin Infect Dis. 2021 Feb 1;34(1):8-15. doi: 10.1097/QCO.0000000000000701. PMID: 33337617.
  3. Gupta RP, Peppa D, Hill A, Gálvez C, Salgado M, Pace M, McCoy L, Griffith S, Thornhill JP, et al. Evidence for HIV- 1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post-analytical treatment interruption: a case report. Lancet HIV. 2020; S2352-3018(20)30069-2. doi:10.1016/S2352-3018(20)30069-2
  4. Fidler S, Stöhr W, Pace M, Dorrell L, Lever A, Pett S, Kinloch-de Loes S, Fox J, Clarke A, Nelson M, Khan M, Thornhill JP, et al. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Lancet. 2020;395(10227):888-898. doi:10.1016/S0140-6736(19)32990-3
  5. Martin GE, Pace M, Shearer FM, Zilber E, Hurst J, Meyerowitz J, Thornhill JP, et al. Levels of Human Immunodeficiency Virus DNA Are Determined Before ART Initiation and Linked to CD8 T-Cell Activation and Memory Expansion. J Infect Dis. 2020;221(7):1135-1145. doi:10.1093/infdis/jiz563
  6. Thornhill JP, Lynch KD, Skelton JK, et al. Vedolizumab use and the associations between α4β7 expression and HIV reservoir in the gut during treated primary HIV infection. AIDS. 2019;33(14):2268-2271. doi:10.1097/QAD.0000000000002344
  7. Thornhill JP*, Pace M*, Martin GE*, et al. CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype. Mucosal Immunol. 2019;12(5):1212-1219. doi:10.1038/s41385-019-0180-2
  8. Thornhill JP*, Martin GE*, Pace M*, et al. CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA. Front Immunol. 2018;9:928. Published 2018 May 4. doi:10.3389/fimmu.2018.00928
  9. Seers T, Vassallo P, Pollock K, Thornhill JP, Fidler S, Foster C. CD4:CD8 ratio in children with perinatally acquired HIV-1 infection. HIV Med. 2018;19(9):668-672. doi:10.1111/hiv.12642
  10. Fidler S, Lewis H, Meyerowitz J, Kuldanek K, Thornhill JP, et al. A pilot evaluation of whole blood finger-prick sampling for point-of-care HIV viral load measurement: the UNICORN study. Sci Rep. 2017;7(1):13658. 2017 Oct 20. doi:10.1038/s41598-017-13287-2
Back to top